Autonomix Medical (NASDAQ:AMIX) Stock Rating Lowered by Wall Street Zen

Autonomix Medical (NASDAQ:AMIX) was downgraded by stock analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Monday, Wall Street Zen reports.

Several other brokerages have also recently commented on AMIX. Weiss Ratings upgraded shares of Autonomix Medical from a “sell (e)” rating to a “sell (e+)” rating in a research note on Tuesday, July 28th. Zacks Research raised shares of Autonomix Medical to a “hold” rating in a report on Tuesday, June 2nd. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Autonomix Medical presently has a consensus rating of “Hold” and an average target price of $42.00.

Autonomix Medical Price Performance

Shares of AMIX opened at $4.21 on Monday. The company’s fifty day moving average price is $5.83 and its 200-day moving average price is $7.26. Autonomix Medical has a 1-year low of $2.44 and a 1-year high of $32.55. The firm has a market capitalization of $4.08 million, a PE ratio of -0.10 and a beta of -1.00.

Autonomix Medical (NASDAQ:AMIX) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($5.02) EPS for the quarter, topping analysts’ consensus estimates of ($6.40) by $1.38. As a group, research analysts anticipate that Autonomix Medical will post -20.17 EPS for the current fiscal year.

Autonomix Medical Company Profile

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.